A randomized, open-label, multiple-dose, crossover phase I study to compare the pharmacokinetic characteristics and safety of Dilatrend SR capsule 32 mg and Dilatrend tablet 25 mg
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Carvedilol (Primary)
- Indications Angina pectoris; Essential hypertension; Heart failure
- Focus Pharmacokinetics
- 31 Jul 2013 New source identified and integrated (Korean Clinical Trials Register: KCT0000787).
- 31 Jul 2013 Status changed from not yet recruiting to active, no longer recruiting as reported by Korean Clinical Trials Register record.
- 05 Apr 2013 New trial record